bioAffinity Tech Stock Price, News & Analysis

bioAffinity Technologies (Nasdaq: BIAF) announced that IP Australia has accepted Australian patent application AU 2019253111 for its platform to assess lung health and predict multiple lung diseases. The application covers methods using flow cytometry with fluorescent probes to detect cellular and molecular signatures in sputum samples. The acceptance adds to bioAffinity’s global estate—18 awarded and 33 pending patents—and complements the company’s flagship CyPath® Lung diagnostic. The patent will be automatically issued three months after acceptance unless a third party files an opposition before issuance.

bioAffinity Technologies (Nasdaq: BIAF) will present research at CHEST 2025 (Oct 19-22) supporting the CyPath® Lung sample collection and transport methods used for its noninvasive lung cancer test.

Rossella Titone, PhD, will present the poster “The Effect of Sputum Storage and Shipping Temperature on Flow Cytometric Outcomes of Sputum-Based Diagnostic Tests” on October 22, 2025 at 10:20 a.m. at poster board #4324. The company said the study validates protocols for home-collected sputum shipped to its lab, with physicians typically receiving results in two days. BioAffinity will be at Booth #2242 and highlighted recent case studies detecting Stage 1A lung cancers.

bioAffinity Technologies (Nasdaq: BIAF) received a notification of allowance from the USPTO for a patent titled “Detection of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning.”

The allowed claim covers an AI-built algorithm and automated flow cytometry system that analyzes sputum cell populations and patient age to predict early-stage lung cancer and supports the company’s commercial CyPath® Lung test. The allowance expands bioAffinity’s global estate to 18 awarded and 33 pending patents across multiple jurisdictions.

bioAffinity Technologies (Nasdaq: BIAF; BIAFW) announced it has regained compliance with Nasdaq continued listing requirements as of a letter dated October 14, 2025. Nasdaq confirmed the company meets Listing Rule 5550(a)(2) (minimum $1.00 closing bid) and Listing Rule 5550(b)(1) (minimum $2.5 million stockholders’ equity), allowing its common stock and warrants to continue trading on the Nasdaq Capital Market under BIAF and BIAFW.

Nasdaq also placed the company under a Mandatory Panel Monitor for one year; failure to comply with the Equity Rule during that period could lead to delisting, though the company can request a new hearing with the Nasdaq Listing Qualifications Hearing Panel before any delisting occurs.

bioAffinity Technologies (NASDAQ: BIAF) closed a registered direct offering of 720,000 shares at $2.50 per share on Oct 9, 2025, raising approximately $1.8 million. WallachBeth Capital acted as sole placement agent. The company said it will use net proceeds for working capital, to support expected growing sales of CyPath® Lung, and for general corporate purposes. The shares were offered under a shelf registration on Form S-3 (File No. 333-275608) declared effective Nov 27, 2023. A prospectus supplement describing the offering terms will be filed with the SEC and made available on the SEC website when available.

bioAffinity Technologies (NASDAQ: BIAF) announced on October 9, 2025 that it closed a registered direct offering of 720,000 common shares at $2.50 per share, raising approximately $1.8 million before offering expenses. WallachBeth Capital acted as sole placement agent. The company said net proceeds will be used for working capital, to support expected growing sales of CyPath® Lung, and for general corporate purposes. The shares were offered under a Form S-3 shelf registration declared effective November 27, 2023, and a prospectus supplement describing the offering terms will be filed with the SEC.

bioAffinity Technologies (NASDAQ: BIAF, BIAFW) entered definitive agreements for a registered direct offering of 720,000 common shares at $2.50 per share, expected to close on or about October 9, 2025. Gross proceeds are expected to be approximately $1.8 million before placement agent fees and offering expenses. WallachBeth Capital is sole placement agent. The company intends to use net proceeds for working capital, to support expected growing sales of CyPath® Lung, and for general corporate purposes. The shares are offered under an effective Form S-3 shelf registration (File No. 333-275608) and a prospectus supplement will be filed with the SEC.

bioAffinity Technologies (NASDAQ: BIAF) announced a registered direct offering of 720,000 shares of common stock at $2.50 per share, expected to close on or about October 9, 2025 subject to customary conditions. Gross proceeds are expected to be approximately $1.8 million before placement agent fees and offering expenses. WallachBeth Capital is sole placement agent. The company intends to use net proceeds for working capital, to support expected growing sales for CyPath® Lung, and for general corporate purposes. The shares are being offered under an effective Form S-3 shelf registration (File No. 333-275608); a prospectus supplement will be filed with the SEC.

bioAffinity Technologies (Nasdaq: BIAF) reported record CyPath® Lung test volumes in Q3 2025, with sales up 95% versus Q2 2025 and a 97% increase in sales for the first nine months of 2025 versus the same period in 2024. The company cited growing adoption by Veterans’ hospitals and expansion in the mid-Atlantic region.

Management highlighted a 77% increase in new patients using CyPath® Lung in Q3 and improved at-home sample collection compliance. Published case studies cited earlier detection (including Stage 1A) and fewer unnecessary invasive procedures.